[go: up one dir, main page]

KR950700938A - 사람 mdri 다중약물 내성 유전자 생성물에 대한 단클론성 항체, 및 그것의 사용방법(a monoclonal antibody to a human mdri multidrug resistance gene product, and uses) - Google Patents

사람 mdri 다중약물 내성 유전자 생성물에 대한 단클론성 항체, 및 그것의 사용방법(a monoclonal antibody to a human mdri multidrug resistance gene product, and uses)

Info

Publication number
KR950700938A
KR950700938A KR1019940703296A KR19940703296A KR950700938A KR 950700938 A KR950700938 A KR 950700938A KR 1019940703296 A KR1019940703296 A KR 1019940703296A KR 19940703296 A KR19940703296 A KR 19940703296A KR 950700938 A KR950700938 A KR 950700938A
Authority
KR
South Korea
Prior art keywords
multidrug resistance
monoclonal antibody
human
gene product
resistance gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019940703296A
Other languages
English (en)
Other versions
KR100249294B1 (ko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/854,881 external-priority patent/US5434075A/en
Application filed filed Critical
Publication of KR950700938A publication Critical patent/KR950700938A/ko
Application granted granted Critical
Publication of KR100249294B1 publication Critical patent/KR100249294B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1019940703296A 1992-03-20 1993-03-17 사람 mdr1 다중약물 내성 유전자 생성물에 대한 단클론성 항체, 및 그것의 사용방법 Expired - Fee Related KR100249294B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7/854881 1992-03-20
US07/854,881 US5434075A (en) 1992-03-20 1992-03-20 Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
US8/032056 1993-03-16
US08/032,056 US5773280A (en) 1992-03-20 1993-03-16 Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
PCT/US1993/002347 WO1993019094A1 (en) 1992-03-20 1993-03-17 A monoclonal antibody to a human mdr1 multidrug resistance gene product, and uses

Publications (2)

Publication Number Publication Date
KR950700938A true KR950700938A (ko) 1995-02-20
KR100249294B1 KR100249294B1 (ko) 2000-03-15

Family

ID=26707922

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940703296A Expired - Fee Related KR100249294B1 (ko) 1992-03-20 1993-03-17 사람 mdr1 다중약물 내성 유전자 생성물에 대한 단클론성 항체, 및 그것의 사용방법

Country Status (10)

Country Link
US (1) US5773280A (ko)
EP (1) EP0644900B1 (ko)
JP (1) JP3631750B2 (ko)
KR (1) KR100249294B1 (ko)
AT (1) ATE242807T1 (ko)
AU (1) AU677221B2 (ko)
CA (1) CA2132540C (ko)
DE (1) DE69333039T2 (ko)
ES (1) ES2201056T3 (ko)
WO (1) WO1993019094A1 (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994088A (en) 1991-03-08 1999-11-30 Board Of Trustees Of The University Of Illinois Methods and reagents for preparing and using immunological agents specific for P-glycoprotein
IT1257893B (it) * 1992-06-17 1996-02-16 Ist Superiore Sanita Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana.
AU5420494A (en) * 1992-11-02 1994-05-24 Yves Claude Nicolau Method of reducing multidrug resistance in cells and tissues
US5866699A (en) * 1994-07-18 1999-02-02 Hybridon, Inc. Oligonucleotides with anti-MDR-1 gene activity
US5686578A (en) * 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
AU3482297A (en) * 1996-06-05 1998-01-05 Eugene Mechetner Reagents and methods for inhibiting cytokine release by blood cells
WO2000014537A2 (en) * 1998-09-04 2000-03-16 Immunomedics, Inc. Immunoconjugate for diagnosis of multidrug resistance
US7294701B2 (en) * 2003-04-02 2007-11-13 Technion Research & Development Foundation Ltd. Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
US20070010465A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070009533A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070009531A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
CA2614392A1 (en) * 2005-07-06 2007-01-18 Kanisa Pharmaceuticals, Inc. Treatment of cancer patients exhibiting activation of the p-glycoprotein efflux pump mechanism
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070009534A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
US20070009535A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204095A (en) * 1980-04-09 1993-04-20 National Research Development Corporation Monoclonal antibodies against hepatitis B virus
US5057598A (en) * 1983-05-06 1991-10-15 Centocor, Inc. Monoclonal antibodies reactive with endotoxin core
US4837306A (en) * 1985-02-25 1989-06-06 The Ontario Cancer Institute Method for selecting hybridomas producing antibodies specific to the P-glycoprotein cell suface antigen and a cDNA clone encoding the C-terminal portion of the antigen
CA1340080C (en) * 1985-03-11 1998-10-13 Dorothee Herlyn Human tumor therapy
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6468398A (en) * 1987-09-08 1989-03-14 Agency Ind Science Techn Monoclonal anti-idiotype antibody and hybridoma and use thereof
US5215913A (en) * 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
US5134075A (en) * 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
US5223400A (en) * 1989-06-01 1993-06-29 The Ontario Cancer Institute Immunoassay method for determining the specificity of binding of a monoclonal antibody to an antigen
US5434075A (en) * 1992-03-20 1995-07-18 Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses

Also Published As

Publication number Publication date
AU4808893A (en) 1993-10-21
DE69333039D1 (de) 2003-07-17
KR100249294B1 (ko) 2000-03-15
JPH07507202A (ja) 1995-08-10
US5773280A (en) 1998-06-30
JP3631750B2 (ja) 2005-03-23
DE69333039T2 (de) 2004-05-06
EP0644900A4 (en) 1995-12-27
ATE242807T1 (de) 2003-06-15
EP0644900A1 (en) 1995-03-29
ES2201056T3 (es) 2004-03-16
CA2132540C (en) 2003-10-07
EP0644900B1 (en) 2003-06-11
WO1993019094A1 (en) 1993-09-30
AU677221B2 (en) 1997-04-17
CA2132540A1 (en) 1993-09-21

Similar Documents

Publication Publication Date Title
KR950700938A (ko) 사람 mdri 다중약물 내성 유전자 생성물에 대한 단클론성 항체, 및 그것의 사용방법(a monoclonal antibody to a human mdri multidrug resistance gene product, and uses)
Altman et al. Molecular events mediating T cell activation
EP2298816A3 (en) Apoptosis induced by an antibody against Her2
WO1999012973A1 (fr) Anticorps monoclonal induisant l'apoptose
CA2165573A1 (en) Anti-.alpha.v-integrin monoclonal antibody
EP0517815A4 (en) An igg-1 human monoclonal antibody reactive with an hiv-1 glycoprotein and method of use
CA2060544A1 (en) Recombinant antibodies specific for a growth factor receptor
DE33578T1 (de) Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches t-zellen-antigen, antikoerper und verfahren.
DE17381T1 (de) Monoklonaler antikoerper gegen menschliche t-zellen, verfahren zu seiner herstellung, ihn produzierende hybridzellinie, ihn enthaltende therapeutische zusammensetzung und ihn verwendendes diagnostisches verfahren.
Eshhar Monoclonal antibody strategy and techniques
Koike et al. Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity
EP0118893A3 (en) Human monoclonal antibodies from lymphocytes of patients with malignant melanoma
AU545181B2 (en) Hybridoma for producing monoclonal antibodies
Brüggen et al. Detection of phenotypic differences on human malignant melanoma lines and their variant sublines with monoclonal antibodies
Sharon et al. Studies on mouse hybridomas secreting IgM or IgA antibodies to α (1→ 6)-linked dextran
DE68922806D1 (de) Monoklonale antikörper und herstellung eines impfstoffes gegen menschliche krebsantigene durch immunisierung mit menschlichem und tierischem mucin und mit synthetischen gluciden-trägerkonjugaten.
CA2049938A1 (en) Monoclonal antibody which recognizes a specific glycopprotein of a human milk-fat globule membrane mucin antigen and said mucin antigen
ATE229080T1 (de) Monoklonale antikörper gegen ck-mb
CA2065874A1 (en) Hybridoma ct43 producing a monoclonal antibody to a mucin epitope of colorectal cancer
Kudo et al. A novel human monoclonal antibody directed to a tumor‐associated antigen
Tsujisaki et al. Preparation and characterization of monoclonal antibodies specific to synthetic peptide of carcinoembryonic antigen
Mechetner et al. Monoclonal antibody to a human mdr1 multidrug resistance gene product, and uses
Shitara et al. Immunoglobulin class switch of anti-ganglioside monoclonal antibody from IgM to IgG
Accolla et al. First report of the production of somatic cell hybrids secreting monoclonal antibodies specific for carcinoembryonic antigen (CEA)
Mozes et al. Characterization and biologic activities of an anti-idiotype-specific T cell line and its derived clones.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20041216

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20051224

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20051224